Baxter International (NYSE:BAX) CEO Robert Parkinson Jr. told analysts earlier today that the company has resolved the issues flagged in a warning letter earlier this year from the FDA.
In January the federal watchdog agency said two plants, which make nutritional and critical-care products, were found to violate good manufacturing practice requirements and failing to file post-market surveillance reports.
No patients were affected by the problems, Parkinson said at the time, adding that the company has already addressed the issues raised in the warning letter.
Today the chief executive said Baxter “successfully worked with the [FDA’s] San Juan district office to resolve concerns at two of our manufacturing sites in Puerto Rico, and we’ve now closed out the warning letter that was received earlier this year,” during a conference call with analysts to discuss its strong third-quarter earnings.
BAX shares were down 2.2 percent to $53.80 as of about 3 p.m. today.